• Je něco špatně v tomto záznamu ?

Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response

J. Kovacova, J. Juracek, A. Poprach, T. Buchler, J. Kopecky, O. Fiala, M. Svoboda, O. Slaby,

. 2018 ; 38 (5) : 2961-2965.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024226

Grantová podpora
NV15-34678A MZ0 CEP - Centrální evidence projektů

BACKGROUND/AIM: Targeted therapy with the tyrosine kinase inhibitor sunitinib is used in the first line of metastatic renal cell carcinoma (mRCC) treatment. The aim of the present study was independent validation of microRNAs (miRNAs) identified in previous studies as biomarkers predicting response to sunitinib therapy. MATERIALS AND METHODS: Based on a literature search, 10 miRNAs were chosen from six relevant studies as candidates for validation: miR-155, miR-484, miR-221, miR-222, miR-425, miR-133, miR-410, miR-141, miR-628 and miR-942. Validation of these miRNAs was performed on cohort of 56 patients with mRCC with extremely good or poor response responses to sunitinib treatment using quantitative reverse transcription-polymerase chain reaction. Patients were divided into either responding (n=24) or non-responding (n=32) groups to sunitinib treatment according to Response Evaluation Criteria in Solid Tumors and progression-free survival (PFS). All patients in the responding group had PFS longer than 18 months, PFS of non-responders was shorter than 6 months in all cases. RESULTS: miR-942 and miR-133 were confirmed as being differentially expressed in tumors of responding and non-responding patients. It was not possible to validate the predictive value of other tested miRNAs, however, expression of miR-221 and miR-425 tended to be positively associated with therapeutic response (p<0.1). We further developed a model based on the combination of miR-942 and miR-133 expression, that enabled identification of non-responding patients with mRCC with sensitivity of 78% and specificity of 79% (area under the curve=0.8071). CONCLUSION: Following further independent validation, detection of these miRNAs may prevent unnecessary and costly approaches to therapy in non-responding patients with mRCC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024226
003      
CZ-PrNML
005      
20201116155445.0
007      
ta
008      
180709s2018 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.12546 $2 doi
035    __
$a (PubMed)29715124
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kovacova, Julia $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
245    10
$a Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response / $c J. Kovacova, J. Juracek, A. Poprach, T. Buchler, J. Kopecky, O. Fiala, M. Svoboda, O. Slaby,
520    9_
$a BACKGROUND/AIM: Targeted therapy with the tyrosine kinase inhibitor sunitinib is used in the first line of metastatic renal cell carcinoma (mRCC) treatment. The aim of the present study was independent validation of microRNAs (miRNAs) identified in previous studies as biomarkers predicting response to sunitinib therapy. MATERIALS AND METHODS: Based on a literature search, 10 miRNAs were chosen from six relevant studies as candidates for validation: miR-155, miR-484, miR-221, miR-222, miR-425, miR-133, miR-410, miR-141, miR-628 and miR-942. Validation of these miRNAs was performed on cohort of 56 patients with mRCC with extremely good or poor response responses to sunitinib treatment using quantitative reverse transcription-polymerase chain reaction. Patients were divided into either responding (n=24) or non-responding (n=32) groups to sunitinib treatment according to Response Evaluation Criteria in Solid Tumors and progression-free survival (PFS). All patients in the responding group had PFS longer than 18 months, PFS of non-responders was shorter than 6 months in all cases. RESULTS: miR-942 and miR-133 were confirmed as being differentially expressed in tumors of responding and non-responding patients. It was not possible to validate the predictive value of other tested miRNAs, however, expression of miR-221 and miR-425 tended to be positively associated with therapeutic response (p<0.1). We further developed a model based on the combination of miR-942 and miR-133 expression, that enabled identification of non-responding patients with mRCC with sensitivity of 78% and specificity of 79% (area under the curve=0.8071). CONCLUSION: Following further independent validation, detection of these miRNAs may prevent unnecessary and costly approaches to therapy in non-responding patients with mRCC.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x genetika $x mortalita $7 D002292
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a nádory ledvin $x farmakoterapie $x genetika $x mortalita $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x analýza $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a ROC křivka $7 D012372
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Juracek, Jaroslav $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital, Faculty of Medicine, Charles University, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic.
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic on.slaby@gmail.com.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 38, č. 5 (2018), s. 2961-2965
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29715124 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20201116155443 $b ABA008
999    __
$a ok $b bmc $g 1316357 $s 1021147
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 38 $c 5 $d 2961-2965 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace